BRCA2 and cancer: Such agents are also of specific interest in cancers that harbor defects in DDR pathway components, where they may create a synthetic lethal-like interaction, as in the case of poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA1 or BRCA2 mutant cancers [2].